JPRN-UMIN000031136已完成未知
A multicenter, open-label, randomized controlled trial to assess the efficacy and safety of appropriate target values for lipid management in patients who have mild to moderate stenosis lesions with high-risk plaques in coronary arteries - A randomized controlled trial comparing the target values for lipid management in patients who have mild to moderate stenosis lesions with high-risk plaques in coronary arteries
ational Hospital Organization Kure Medical Center0 个研究点目标入组 95 人开始时间: 2018年3月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 95
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)With a significant stenosis of the coronary artery which is an indication for revascularization 2)Having a history of myocardial infarction 3)Having a history of coronary artery revascularization (PCI or CABG) 4)Whose LDL-C value already satisfies the secondary prevention criteria in JAS Guideline for Prevention of Atherosclerotic Cardiovascular Diseases at the time of registration 5)Diagnosed with familial hypercholesterolemia-homozygote 6)With poorly controlled diabetes whose HbA1c value is 10% or more 7)With BMI of less than 17 kg/m2 8)With chronic kidney disease whose eGFR value is 30 mL/min/1.73 m2 or less 9)Having a history of complications suspected to be related to the contrast medium 10)With thyroid disease requiring treatment 11)Confirmed bronchial asthma, multiple myeloma, macroglobulinemia, tetany, or pheochromocytoma 12)Having a history of side effects caused by taking statins 13)In poor compliance with medication due to dementia 14)Judged to be inappropriate for participation in this study by the principal investigator/sub-investigators
研究者
相似试验
招募中
不适用
A multi-center, open-label, randomized controlled clinical trial study on the treatment of Delta novel coronavirus pneumonia (COVID-19) based on ''three-party'' syndrome differentiation and treatmentDelta Novel Coronavirus PneumoniaITMCTR2100005149Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine)
进行中（未招募）
不适用
A multi-center, open-label, randomized, controlled, parallel-group study to assess efficacy and safety of an extended flexible regimen of the combined oral contraceptive SH T00186D (0.02 mg ethinylestradiol as beta-cyclodextrin clathrate and 3 mg drospirenone) compared to the conventional regimen of SH T00186D in the treatment of primary dysmenorrhea - SH T00186 in the treatment of primary dysmenorrheawomen suffering from primary dysmenorrheaEUCTR2006-004899-13-DEBayer Schering Pharma AG
进行中（未招募）
1 期
A multi-center, open-label, randomized, controlled, parallel-group study to assess efficacy and safety of an extended flexible regimen of the combined oral contraceptive SH T00186D (0.02 mg ethinylestradiol as beta-cyclodextrin clathrate and 3 mg drospirenone) compared to the conventional regimen of SH T00186D in the treatment of primary dysmenorrhea - SH T00186 in the treatment of primary dysmenorrheawomen suffering from primary dysmenorrheaMedDRA version: 9.1Level: LLTClassification code 10036689Term: Primary dysmenorrhoeaEUCTR2006-004899-13-GBBayer Schering Pharma AG216
尚未招募
Unknown
A multi-center open-label randomized controlled trial to evaluate the efficacy of the Mantis Clip for defect closure following colorectal endoscopic submucosal dissectioJPRN-UMIN000054070The Jikei University School of Medicine250
进行中（未招募）
1 期
A clinical trial where a change in medication can reduce the incidence of diabetes after renal transplantation.Prophylaxis of rejection in kidney allograft recipients (by immunosuppression)MedDRA version: 14.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2012-000451-13-SETransplant Institute, Sahlgrenska University Hospital223